Literature DB >> 21600854

Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction.

Marc R Parrish1, Michael J Ryan, Porter Glover, Justin Brewer, Lillian Ray, Ralf Dechend, James N Martin, Babbette B Lamarca.   

Abstract

BACKGROUND: Previous investigations suggested that agonistic autoantibodies to the angiotensin II type I receptor (AT1-AA) might mediate a hypertensive response through dysregulation of the endothelin-1 system. AT1-AA induced hypertension was attenuated by the AT1 receptor and/or endothelin-1 type A receptor antagonists.
OBJECTIVES: This study was undertaken to determine if AT1-AA induced hypertension was associated with renal endothelial dysfunction.
METHODS: We compared the vascular reactivity of renal interlobar arteries from normal pregnant control rats and AT1-AA long-term infused pregnant rats in the presence and absence of endothelin type A (ET(A)) receptor antagonism. Renal endothelial function was tested using isolated renal interlobar arteries in a pressure myograph, which were exposed to acetylcholine or sodium nitroprusside.
RESULTS: Vasodilatory responses to the endothelial-dependent agonist acetylcholine were impaired in AT1-AA rats (74 [10]%) compared with normal pregnant controls (95 [5]%, P < 0.05). In the presence of ET(A) receptor antagonism, no differences were observed between controls or the AT1-AA treated group with regard to endothelial-dependent (acetylcholine) relaxation.
CONCLUSION: AT1-AA induced hypertension during pregnancy was associated with disparate renal endothelial responses to acetylcholine. The difference in renal vascular responses between AT1-AA and normal pregnant rats was abolished by ET(A) receptor blockade.
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21600854      PMCID: PMC3225254          DOI: 10.1016/j.genm.2011.04.003

Source DB:  PubMed          Journal:  Gend Med        ISSN: 1550-8579


  20 in total

1.  Implication of an AGT haplotype in a multigene association study with pregnancy hypertension.

Authors:  Sébastien Lévesque; Jean-Marie Moutquin; Carmen Lindsay; Marie-Claude Roy; François Rousseau
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

Review 2.  Role of the renin-angiotensin system in the pathogenesis of preeclampsia.

Authors:  Dinesh M Shah
Journal:  Am J Physiol Renal Physiol       Date:  2005-04

3.  AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor.

Authors:  R Dechend; V Homuth; G Wallukat; J Kreuzer; J K Park; J Theuer; A Juepner; D C Gulba; N Mackman; H Haller; F C Luft
Journal:  Circulation       Date:  2000-05-23       Impact factor: 29.690

Review 4.  Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy.

Authors:  James M Roberts; Gail Pearson; Jeff Cutler; Marshall Lindheimer
Journal:  Hypertension       Date:  2003-02-10       Impact factor: 10.190

Review 5.  Activating auto-antibodies against the AT1 receptor in preeclampsia.

Authors:  Ralf Dechend; Dominik N Müller; Gerd Wallukat; Volker Homuth; Manja Krause; Joachim Dudenhausen; Friedrich C Luft
Journal:  Autoimmun Rev       Date:  2005-01       Impact factor: 9.754

6.  Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.

Authors:  G Wallukat; V Homuth; T Fischer; C Lindschau; B Horstkamp; A Jüpner; E Baur; E Nissen; K Vetter; D Neichel; J W Dudenhausen; H Haller; F C Luft
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

7.  AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase.

Authors:  Ralf Dechend; Christiane Viedt; Dominik N Müller; Bernhard Ugele; Ralf P Brandes; Gerd Wallukat; Joon-Keun Park; Jurgen Janke; Peter Barta; Jurgen Theuer; Anette Fiebeler; Volker Homuth; Rainer Dietz; Hermann Haller; Jörg Kreuzer; Friedrich C Luft
Journal:  Circulation       Date:  2003-02-24       Impact factor: 29.690

8.  Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.

Authors:  Giorgio Mello; Elena Parretti; Cinzia Fatini; Chiara Riviello; Francesca Gensini; Mauro Marchionni; Gian Franco Scarselli; Gian Franco Gensini; Rosanna Abbate
Journal:  Hypertension       Date:  2004-11-22       Impact factor: 10.190

9.  Vascular ENaC proteins are required for renal myogenic constriction.

Authors:  Nikki L Jernigan; Heather A Drummond
Journal:  Am J Physiol Renal Physiol       Date:  2005-05-24

10.  Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.

Authors:  Babbette LaMarca; Marc Parrish; Lillian Fournier Ray; Sydney R Murphy; Lyndsay Roberts; Porter Glover; Gerd Wallukat; Katrin Wenzel; Kathy Cockrell; James N Martin; Michael J Ryan; Ralf Dechend
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

View more
  27 in total

1.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

2.  Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system.

Authors:  Kedra Wallace; Sarah Novotny; Judith Heath; Janae Moseley; James N Martin; Michelle Y Owens; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-05-30       Impact factor: 3.619

3.  Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats.

Authors:  Denise C Cornelius; Javier Castillo; Justin Porter; Lorena M Amaral; Nathan Campbell; Adrienne Paige; Alexia J Thomas; Ashlyn Harmon; Mark W Cunningham; Kedra Wallace; Florian Herse; Gerd Wallukat; Ralf Dechend; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-26       Impact factor: 3.619

Review 4.  Elucidating immune mechanisms causing hypertension during pregnancy.

Authors:  Babbette LaMarca; Denise Cornelius; Kedra Wallace
Journal:  Physiology (Bethesda)       Date:  2013-07

Review 5.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

6.  IL-10 supplementation increases Tregs and decreases hypertension in the RUPP rat model of preeclampsia.

Authors:  Ashlyn Harmon; Denise Cornelius; Lorena Amaral; Adrienne Paige; Florian Herse; Tarek Ibrahim; Gerd Wallukat; Jessica Faulkner; Janae Moseley; Ralf Dechend; Babbette LaMarca
Journal:  Hypertens Pregnancy       Date:  2015-05-21       Impact factor: 2.108

7.  An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia.

Authors:  Denise C Cornelius; Lorena M Amaral; Ashlyn Harmon; Kedra Wallace; Alexia J Thomas; Nathan Campbell; Jeremy Scott; Florian Herse; Nadine Haase; Janae Moseley; Gerd Wallukat; Ralf Dechend; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-19       Impact factor: 3.619

8.  Pregnant rats treated with a high-fat/prooxidant Western diet with ANG II and TNF-α are resistant to elevations in blood pressure and renal oxidative stress.

Authors:  Mark W Cunningham; Crystal A West; Xuerong Wen; Aihua Deng; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-03-25       Impact factor: 3.619

Review 9.  Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension.

Authors:  Florian Herse; Babbette LaMarca
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

10.  Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.

Authors:  J S Possomato-Vieira; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.